摘要:
The present invention provides novel solid forms of pharmaceutically active agents and therapeutic uses thereof. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
摘要:
Bicyclic heterocyclic derivatives of formula I useful in inhibiting PDGF receptor mediated biological activity. wherein A is and R1, R1a, R2, R3, R4, R5, R6 and X are as defined herein.
摘要:
Bicyclic heterocyclic derivatives of formula I useful in inhibiting PDGF receptor mediated biological activity. wherein A is and R1, R1a, R2, R3, R4, R5, R6 and X are as defined herein.
摘要:
Bicyclic heterocyclic derivatives of formula I useful in inhibiting PDGF receptor mediated biological activity. wherein A is and R1, R1a, R2, R3, R4, R5, R6 and X are as defined herein.
摘要:
The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of PDGFR (PDGFRα, PDGFRβ) kinases or c-kit and PDGFR (PDGFRα, PDGFRβ) kinases.
摘要:
Compounds of formula I: in free or salt or solvate form, where R1, R2, R3 and R20 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described. These compounds are useful for the treatment of inflammatory or obstructive airways diseases such as pulmonary hypertension, pulmonary fibrosis, liver fibrosis, cancer, muscle diseases such as muscle atrophies and muscle dystrophies, and systemic skeletal disorders such as osteoporosis.
摘要:
Compounds of formula I: in free or salt or solvate form, where R1, R2, R3 and R20 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described. These compounds are useful for the treatment of inflammatory or obstructive airways diseases such as pulmonary hypertension, pulmonary fibrosis, liver fibrosis, cancer, muscle diseases such as muscle atrophies and muscle dystrophies, and systemic skeletal disorders such as osteoporosis.
摘要:
A compound of Formula (II) and (III), or a mixture of any two or more thereof; wherein M is Ti or Zr; R3 at each occurrence is H, F, Cl, Br, I, CN, OR4, NR5R6, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, unsubstituted heterocyclyl, or substituted or unsubstituted heterocyclylalkyl; R4 is H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, unsubstituted heterocyclyl, or substituted or unsubstituted heterocyclylalkyl; R5 and R6 are independently H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclylalkyl, or R5 and R6 may join to form a heterocyclic ring containing the N to which they are attached; and n′=0-4. Such compounds form optically transparent and/or clear films or particles or may be used to prepare such materials.
摘要翻译:式(II)和(III)的化合物或其任何两种或更多种的混合物; 其中M是Ti或Zr; R 3在每次出现时为H,F,Cl,Br,I,CN,OR4,NR5R6,取代或未取代的烷基,取代或未取代的环烷基,取代或未取代的环烷基烷基,未取代的杂环基或取代或未取代的杂环基烷基; R4是H,取代或未取代的烷基,取代或未取代的环烷基,取代或未取代的环烷基烷基,未取代的杂环基或取代或未取代的杂环基烷基; R 5和R 6独立地为H,取代或未取代的烷基,取代或未取代的环烷基,取代或未取代的杂环基烷基,或R 5和R 6可以连接形成含有它们所连接的N的杂环; 并且n'= 0-4。 这些化合物形成光学透明和/或透明的薄膜或颗粒,或可用于制备这种材料。
摘要:
A compound of Formula (II) and (III), or a mixture of any two or more thereof; wherein M is Ti or Zr; R3 at each occurrence is H, F, Cl, Br, I, CN, OR4, NR5R6, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, unsubstituted heterocyclyl, or substituted or unsubstituted heterocyclylalkyl; R4 is H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, unsubstituted heterocyclyl, or substituted or unsubstituted heterocyclylalkyl; R5 and R6 are independently H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclylalkyl, or R5 and R6 may join to form a heterocyclic ring containing the N to which they are attached; and n′=0-4. Such compounds form optically transparent and/or clear films or particles or may be used to prepare such materials.
摘要翻译:式(II)和(III)的化合物或其任何两种或更多种的混合物; 其中M是Ti或Zr; R 3在每次出现时是H,F,Cl,Br,I,CN,OR4,NR5R6,取代或未取代的烷基,取代或未取代的环烷基,取代或未取代的环烷基烷基,未取代的杂环基或取代或未取代的杂环基烷基; R4是H,取代或未取代的烷基,取代或未取代的环烷基,取代或未取代的环烷基烷基,未取代的杂环基或取代或未取代的杂环基烷基; R 5和R 6独立地为H,取代或未取代的烷基,取代或未取代的环烷基,取代或未取代的杂环基烷基,或R 5和R 6可以连接形成含有它们所连接的N的杂环; 并且n'= 0-4。 这些化合物形成光学透明和/或透明的薄膜或颗粒,或可用于制备这种材料。